GlassScriptPhysician profile
Richard C Harker
NPI 1780670885
$28,231.96
in general payments reported to CMS, 2019-2025
54 companies · $3,493 in 2025
The $3,493 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,275 · 2020: $7,570 · 2021: $5,519 · 2022: $3,324 · 2023: $2,976 · 2024: $3,076 · 2025: $3,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,545.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,217.44 | 2019-2021 | |
| Novo Nordisk INC | $3,474.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,742.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,700.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,510.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,307.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,251.76 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $1,219.27 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,113.17 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $969.35 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $895.55 | 2019-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $429.29 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $391.59 | 2020-2021 | |
| Exact Sciences Corporation | $369.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $343.93 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Harker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.